SAP depletion enables amyloid clearance in systemic amyloidosis
PrimaryPentraxin's systemic amyloidosis program is based on the claim that serum amyloid P component (SAP) is a pathogenic constituent of amyloid deposits and that depleting circulating SAP with CPHPC/miridesap can expose deposited SAP-associated amyloid to immune clearance. Adding the anti-SAP antibody dezamizumab is intended to target residual SAP in amyloid deposits and trigger removal of amyloid material from affected tissues. Testable predictions include reduced circulating SAP after miridesap, antibody localization to amyloid deposits, reduced amyloid burden in organs, and clinical improvement or stabilization in systemic amyloidosis patients if amyloid clearance is achieved.
Popperian evaluation
The biological starting point is credible: SAP is repeatedly described as present in amyloid deposits, CPHPC/miridesap can deplete circulating SAP, and the antibody strategy has a clear target after depletion. The weaker premise is causal. The evidence supports SAP as a targetable constituent, but the claim that SAP drives deposit persistence rather than merely marking amyloid is still an assumption with medium confidence.
Supporting evidence: Multiple nodes identify SAP as associated with amyloid deposits in affected tissues and targetable within amyloid material.; The evidence set includes Nature 2002, Nature 2006, PNAS 2009, Nature 2010, NEJM 2015, and Sci Transl Med 2018 publications tied to SAP biology, SAP depletion, antibody targeting, and amyloid burden measurements.; CPHPC/miridesap is specifically supported as reducing circulating SAP in treated systemic amyloidosis patients.
Counter evidence: The dossier labels the persistence or pathogenic role of SAP as a medium-confidence assumption, not a settled fact.; SAP could be a useful handle on amyloid deposits without being a major causal driver of the disease process.
The theory explains a linked chain of observations: deplete soluble SAP, expose deposited SAP, deliver anti-SAP antibody, then look for organ amyloid reduction and clinical stabilization. That is a coherent mechanism. The gap is that reduced circulating SAP and antibody localization can be explained by target engagement alone. They do not prove that immune clearance of amyloid is the main driver of clinical benefit.
Supporting evidence: The evidence context reports pharmacologic SAP depletion, antibody targeting, and amyloid burden or clinical outcome measurements.; The theory connects a molecular intervention to tissue-level readouts: deposited SAP binding and reduced amyloid burden in affected organs.; The NEJM 2015 and Sci Transl Med 2018 publications are linked to the central translational tests of depletion, targeting, and outcomes.
Counter evidence: Clinical improvement or stabilization is conditional on actual amyloid clearance, and the dossier marks that link as medium confidence.; Alternative explanations remain possible, including target engagement without enough tissue clearance, disease stabilization from background care, or organ-specific measurement noise.
This is strongly falsifiable. The theory makes concrete predictions at several levels: circulating SAP should fall after miridesap, dezamizumab should localize to SAP-retaining deposits, organ amyloid burden should decline, and patients should improve or stabilize if clearance is real. A clean failure at the tissue level after confirmed depletion and antibody delivery would hit the central claim hard.
Supporting evidence: Miridesap is predicted to reduce circulating SAP in treated systemic amyloidosis patients.; Dezamizumab is predicted to localize to amyloid deposits that retain SAP after miridesap treatment.; Combined miridesap and dezamizumab treatment is predicted to reduce amyloid burden in affected organs.; Clinical improvement or stabilization is predicted if amyloid clearance is achieved.
Counter evidence: Some clinical endpoints may be slow or organ-dependent, so a short trial could miss a real effect.; A failure in one amyloidosis subtype would not automatically falsify every SAP-targeting version of the theory.
Reasoning tree
Public endorsements
Pepys is publicly tied to Pentraxin and to SAP-focused amyloid research: the company says it was founded by him and holds IP from his research group, and UCL says he worked on amyloid for 40 years with a major focus on serum amyloid P component. That supports clear public association with the SAP program, but the evidence here does not show him explicitly stating this full mechanism, namely SAP depletion exposing deposits to immune clearance and anti-SAP antibody driven removal.
Evidence publication IDs: 2b24c615-ff4a-4c37-8933-6a71091c68e9, 6dfa4712-4c59-4223-9753-f658dc58adfd, 9d938b14-b6b6-4528-a65e-48de4d305d8b, bc11c538-4e3b-4844-96d0-89a4732e6a3d